Dr. Linda Stork, Professor of Pediatrics, Division of Hematology and Oncology, School of Medicine provides this month’s update:
The Doernbecher Blood and Cancer program was chosen by Children’s Oncology Group (COG) to become a new member of the early phase clinical trials consortium (PEP-CTN), with Dr. Bill Chang (former Kiwanis fellow; now Professor) as our Principal Investigator starting Jan 31, 2021. This means that we can offer even more innovative clinical trials to our oncology patients (children, adolescents, and young adults) if their cancer recurs. We are one of about 20 programs in US and Canada able to provide these Phase I trials to patients.
As principal investigator (PI) for Doernbecher on this grant from COG, Bill is ultimately responsible for the safe and ethical conduct of these studies – so as not to “harm” any of our patients as study participants. He works very closely with our outstanding clinical research associates (CRAs: ee have 8 such individuals now in our Division) to open up the studies through our institutional review board, electronically report all the data that COG needs for any of our patients on study, and make sure the rest of us follow the study requirements – medications and lab/imaging tests, for our patients on these studies. The National Institutes of Health and various federal organizations set safety requirements and ultimately oversee the conduct of all these studies. Also, some money for CRA salaries comes with the grant.
In other news…
Dr. Pat Demartino (3rd yr fellow) has already produced two 1st author peer-reviewed publications:
“Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018”, published in JAMA Intern Med, 12/20.
“A Budget Impact Analysis of Gene Therapy for Sickle Cell Disease: The Medicaid Perspective”, to be published in JAMA Peds in 3/2021.
Dr. Florence Choo (3rd yr fellow): submitted an abstract to the American Society of Pediatric Hematology/Oncology 4/2021 meeting describing her research project on a rare type of sarcoma and results from her work in Dr. Davare’s lab:
“Novel Mutations and Role of Molecularly Targeted Therapy in Pediatric Spindle Cell Rhabdomyosarcoma”
Andrea Gillespie (1st yr fellow): published a review of an article, as 1st author in Journal of Pediatrics in Jan 2021:
“The Status of Pediatric Extracorporeal Life Support According to the National Inpatient Sample.”